Cyclosporine excretion into breast milk. 2003

Myla E Moretti, and Michael Sgro, and David W Johnson, and Reg S Sauve, and Mary J Woolgar, and Anna Taddio, and Zul Verjee, and Esther Giesbrecht, and Gideon Koren, and Shinya Ito
The Motherisk Program, The Hospital for Sick Children, Toronto, Ontario, Canada.

Although many female patients of childbearing age who are receiving cyclosporine have successful pregnancies, these women may be advised not to breast-feed. During recent years, cases of uneventful pregnancies and subsequent successful breast-feeding have been reported in the literature. The infant's blood cyclosporine concentration was usually very low. Based on these findings and the lack of detectable adverse effects, some investigators have suggested that women on cyclosporine may breast-feed, challenging the conventional view that cyclosporine is contraindicated during breast-feeding. Here, we report our experience with cyclosporine use during breast-feeding in five mother-infant pairs. We show a wide range of infant exposures to the drug in milk, noting that one of the infants had therapeutic blood concentrations of cyclosporine despite relatively low concentrations of the drug in milk.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008895 Milk, Human Milk that is produced by HUMAN MAMMARY GLANDS. Breast Milk,Human Milk,Milk, Breast
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D016030 Kidney Transplantation The transference of a kidney from one human or animal to another. Grafting, Kidney,Renal Transplantation,Transplantation, Kidney,Transplantation, Renal,Kidney Grafting,Kidney Transplantations,Renal Transplantations,Transplantations, Kidney,Transplantations, Renal
D016572 Cyclosporine A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). Cyclosporin A,Ciclosporin,CsA-Neoral,CyA-NOF,Cyclosporin,Cyclosporine A,Neoral,OL 27-400,Sandimmun,Sandimmun Neoral,Sandimmune,CsA Neoral,CsANeoral,CyA NOF,OL 27 400,OL 27400

Related Publications

Myla E Moretti, and Michael Sgro, and David W Johnson, and Reg S Sauve, and Mary J Woolgar, and Anna Taddio, and Zul Verjee, and Esther Giesbrecht, and Gideon Koren, and Shinya Ito
May 1982, British journal of clinical pharmacology,
Myla E Moretti, and Michael Sgro, and David W Johnson, and Reg S Sauve, and Mary J Woolgar, and Anna Taddio, and Zul Verjee, and Esther Giesbrecht, and Gideon Koren, and Shinya Ito
May 1980, British journal of clinical pharmacology,
Myla E Moretti, and Michael Sgro, and David W Johnson, and Reg S Sauve, and Mary J Woolgar, and Anna Taddio, and Zul Verjee, and Esther Giesbrecht, and Gideon Koren, and Shinya Ito
June 1979, British journal of clinical pharmacology,
Myla E Moretti, and Michael Sgro, and David W Johnson, and Reg S Sauve, and Mary J Woolgar, and Anna Taddio, and Zul Verjee, and Esther Giesbrecht, and Gideon Koren, and Shinya Ito
April 2003, Advanced drug delivery reviews,
Myla E Moretti, and Michael Sgro, and David W Johnson, and Reg S Sauve, and Mary J Woolgar, and Anna Taddio, and Zul Verjee, and Esther Giesbrecht, and Gideon Koren, and Shinya Ito
January 1990, Acta dermato-venereologica,
Myla E Moretti, and Michael Sgro, and David W Johnson, and Reg S Sauve, and Mary J Woolgar, and Anna Taddio, and Zul Verjee, and Esther Giesbrecht, and Gideon Koren, and Shinya Ito
January 1987, Pharmacotherapy,
Myla E Moretti, and Michael Sgro, and David W Johnson, and Reg S Sauve, and Mary J Woolgar, and Anna Taddio, and Zul Verjee, and Esther Giesbrecht, and Gideon Koren, and Shinya Ito
March 2000, British journal of clinical pharmacology,
Myla E Moretti, and Michael Sgro, and David W Johnson, and Reg S Sauve, and Mary J Woolgar, and Anna Taddio, and Zul Verjee, and Esther Giesbrecht, and Gideon Koren, and Shinya Ito
March 1989, Lancet (London, England),
Myla E Moretti, and Michael Sgro, and David W Johnson, and Reg S Sauve, and Mary J Woolgar, and Anna Taddio, and Zul Verjee, and Esther Giesbrecht, and Gideon Koren, and Shinya Ito
November 1990, DICP : the annals of pharmacotherapy,
Myla E Moretti, and Michael Sgro, and David W Johnson, and Reg S Sauve, and Mary J Woolgar, and Anna Taddio, and Zul Verjee, and Esther Giesbrecht, and Gideon Koren, and Shinya Ito
August 2018, Journal of clinical psychopharmacology,
Copied contents to your clipboard!